Tophaceous Gout
Conditions
Keywords
Tophaceous Gout, Dotinurad, Allopurinol, Hyperuricemia
Brief summary
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.
Interventions
DRUGAllopurinol
Over-encapsulated tablets containing active drug substance administered orally (PO).
DRUGDotinurad
Over-encapsulated tablets containing active drug substance administered PO.
Sponsors
Crystalys Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Between 18 and 75 years of age (inclusive) at the time of signing informed consent. 2. Diagnosis of gout based on 2015 American College of Rheumatology-European Union League Against Rheumatism (ACR-EULAR) criteria for at least 1 year. 3. Has ≥1 measurable tophus on the hands/wrists and/or feet/ankles between Screening and Day 1. A measurable tophus is defined as ≥5 mm and ≤30 mm in the longest diameter. 4. sUA level ≥5.0 mg/dL at Screening Visit 1 (Day -35 Visit) and Screening Visit 2 (Day -7 Visit). 5. Female participants of childbearing potential must have a negative serum pregnancy test at Screening Visit 1 (Day -35 Visit) and Screening Visit 2 (Day -7 Visit), a negative urine pregnancy test on Day 1, and must not be breastfeeding. 6. Fertile male participants and female participants of childbearing potential must be willing to completely abstain from heterosexual sex or agree to use acceptable contraception from the time of signing informed consent through 30 days after the last dose of study drug.
Exclusion criteria
1. History of or presence of kidney stones within 1 year prior to Screening. 2. History of or presence of malignancy in the last 5 years other than treated cutaneous basal or squamous cell carcinoma. 3. Hypersensitivity or intolerance to dotinurad or to colchicine and nonsteroidal anti-inflammatory drugs (NSAIDs). 4. Known or suspected history of drug abuse, a positive drug test at Screening Visit 1, or a recent history of alcohol abuse. 5. Known history of or positive results for human immunodeficiency virus (HIV), Hepatitis B Surface Antigen (HBsAg), or Hepatitis C antibodies (HCV) during Screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants with an sUA Level <5.0 mg/dL at Week 24 | Week 24 |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of Participants who Experience Complete Response (CR) or Partial Response (PR) of ≥1 Target Tophus at Week 76 | Week 76 |
| Percentage of Participants who Experience CR of ≥1 Target Tophus at Week 76 | Week 76 |
| Percentage of Participants with an sUA Level <4.0 mg/dL at Week 24 | Week 24 |
| Mean Rate of Gout Flares Requiring Treatment from Week 36 Through Week 76 | Week 36 through Week 76 |
| Percentage of Participants with an sUA Level <5.0 mg/dL at Week 24 and No Gout Flares Requiring Treatment from Week 36 Through Week 76 | Week 24 and Week 36 through Week 76 |
| Mean Change from Baseline in sUA at Week 24 | Baseline and Week 24 |
| Mean Percent Change from Baseline in the Sum of the Areas for all Target Tophi at Each Visit | Baseline to Week 80 |
| Percentage of Participants who Do Not have a Gout Flare Requiring Treatment from Week 36 through Week 76 | Week 36 through Week 76 |
| Percentage of Participants with an sUA Level <5.0 mg/dL at Each Visit | Up to Week 80 |
| Percentage of Participants with an sUA Level <4.0 mg/dL at Each Visit | Up to Week 80 |
| Percentage of Participants with an sUA Level <3.0 mg/dL at Each Visit | Up to Week 80 |
| Absolute Change from Baseline in sUA Levels at Each Visit | Baseline to Week 80 |
| Percent Change from Baseline in sUA Levels at Each Visit | Baseline to Week 80 |
| Percentage of Participants with a Gout Flare Requiring Treatment at Each Month Between Week 24 and the End of Study | Week 24 to Week 80 |
| Percentage of Participants with Treatment-emergent Adverse Events (TEAEs) | Up to Week 80 |
| Percentage of Participants with Serious Adverse Events (SAEs) | Up to Week 80 |
Countries
United States
Contacts
CONTACTClinical Trial Lead
Outcome results
None listed